TREATMENT PATTERNS AND HEALTH OUTCOMES AMONG PATIENTS WITH RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER IN THE UNITED STATES AND WESTERN EUROPE
Author(s)
Gianoukakis AG1, Flores NM2, Pelletier CL3, DiBonaventura M2, Forsythe A3, Wolfe G2, Rege J3, Taylor MH4
1University of California, Los Angeles, Torrance, CA, USA, 2Kantar Health, New York, NY, USA, 3Eisai Inc, Woodcliff Lake, NJ, USA, 4Oregon Health & Science University, Division of Hematology & Medical Oncology, Portland, OR, USA
OBJECTIVES: Most patients with differentiated thyroid cancer (DTC) have an excellent prognosis after receiving standard treatment, consisting of surgery and often adjuvant radioactive iodine (RAI). However, a subgroup of patients prove to have progressive DTC which is refractory to RAI (RRDTC). Treatment options for RRDTC are limited. This study investigated the treatment patterns and health care resource utilization of patients with RRDTC. METHODS: Data were collected by performing a retrospective chart review study in the US and 5EU (France, Germany, Italy, Spain, UK) with physicians recruited from an online panel. Physicians provided clinical information on 1 to 4 of their RRDTC patients in an online survey. Demographics, disease history, treatment information, and healthcare resource were included and reported descriptively. Healthcare resource use was compared across treatment classes using general linear models. RESULTS:
Conference/Value in Health Info
2014-11, ISPOR Europe 2014, Amsterdam, The Netherlands
Value in Health, Vol. 17, No. 7 (November 2014)
Code
PCN1
Topic
Clinical Outcomes, Epidemiology & Public Health
Topic Subcategory
Comparative Effectiveness or Efficacy, Disease Classification & Coding, Relating Intermediate to Long-term Outcomes
Disease
Diabetes/Endocrine/Metabolic Disorders, Oncology